Licensing · GCC · Announced 8 Oct 2026
Elpen → ADCAN Pharma
Licensing deal between Elpen (Greece) and ADCAN Pharma (United Arab Emirates), announced 8 Oct 2026.
Parties: Elpen (Greece) → ADCAN Pharma (United Arab Emirates)
- Deal type
- Licensing
- Value
- Not stated
- Territory
- UAE, KSA and rest of Middle East
- Therapeutic area
- Cardiovascular
- Asset
- Licensing, technology transfer and local manufacturing agreement — cardiovascular and respiratory portfolio; respiratory scope includes device-based inhaled therapies (Elpenhaler platform class)
- Announced
- 8 Oct 2026
Our analysis
The most technically demanding of ADCAN's five CPHI deals.
Our dataset shows Elpen already carries ~94 regional registrations (UAE 27, Bahrain 23, Iraq 19, Saudi 16) — a cardiovascular and respiratory book that includes its Elpenhaler inhaled platform.
The full analysis is free to read with a work email on this page.
Source: Zawya